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Abstract
The skeletal muscle ryanodine receptor plays a crucial role in excitation–contraction (EC)
coupling and is implicated in various congenital myopathies. The periodic paralyses are a
heterogeneous, dominantly inherited group of conditions mainly associated with mutations in the
SCN4A and the CACNA1S genes. The interaction between RyR1 and DHPR proteins underlies
depolarization-induced Ca2+ release during EC coupling in skeletal muscle. We report a 35-year-
old woman presenting with signs and symptoms of a congenital myopathy at birth and repeated
episodes of generalized, atypical normokalaemic paralysis in her late teens. Genetic studies of this
patient revealed three heterozygous RYR1 substitutions (p.Arg2241X, p.Asp708Asn and
p.Arg2939Lys) associated with marked reduction of the RyR1 protein and abnormal DHPR
distribution. We conclude that RYR1 mutations may give rise to both myopathies and atypical
periodic paralysis, and RYR1 mutations may underlie other unresolved cases of periodic paralysis
with unusual features.
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The skeletal muscle ryanodine receptor (RYR1) gene on chromosome 19q13.1 encodes the
principal sarcoplasmic reticulum (SR) calcium release channel (RyR1), which plays a
crucial role in excitation– contraction (EC) coupling by releasing calcium from the SR
following muscle activation. RYR1 mutations have been implicated in a wide range of
conditions (for review [1]). Among these are malignant hyperthermia susceptibility (MHS)
[2] and various congenital myopathies including “core myopathies” with central cores
(Central Core Disease, CCD) [3], multiple cores (Multi-minicore disease, MmD) with
external ophthalmoplegia [4] and, rarely, Centronuclear Myopathy (CNM) [5]. Whilst MHS
is dominantly inherited, CCD involves both dominant and recessive inheritance. MmD with
external ophthalmoplegia is associated with recessive inheritance and quantitative defects of
RyR1 protein expression, due to epigenetic allele silencing [6] or compound heterozygosity
for RYR1 null and missense mutations [7,8].
The periodic paralyses are a genetically heterogeneous group of rare, dominantly inherited
conditions characterized by episodic weakness and divided into hyperkalaemic periodic
paralysis (HYPP, OMIM 170500), mainly caused by SCN4A missense mutations [9,10], and
hypokalaemic periodic paralysis (HOKPP, OMIM170400), predominantly associated with
mutations in the CACNA1S gene [11], which encodes the α1S subunit of the dihydro-
pyridine receptor (DHPR) or L-type calcium channel in skeletal muscle. The close
functional relationship between the DHPR and RyR1 is reflected by their co-localization and
linkage within the triad [12], convergence of associated clinical phenotypes, and findings of
abolished EC coupling in animal models lacking either of the two proteins [13,14]. Whilst
MHS has been reported in one French family harbouring a dominant CACNA1S mutation
[15], prior studies failed to provide a definitive link between RYR1 mutations and periodic
paralysis [16].
We report a 35-year-old patient with Multi-minicore disease (MmD) with external
ophthalmoplegia and additional episodes of atypical periodic paralysis associated with
compound heterozygosity for a nonsense and missense mutations in RYR. Detailed
neurophysiological and immunohistochemical studies in this patient suggested a dramatic
reduction in RyR1 protein expression with resulting marked disruption of the EC coupling
machinery.
2. Patient and methods
2.1. Patient
This 35-year-old female was the oldest child of a healthy non-consanguineous couple of
Irish ancestry. Two younger brothers were healthy and her deceased sister had suffered from
psychiatric problems. There was no preceding family history of neuromuscular disorders.
She presented at birth with hypotonia, respiratory impairment and feeding difficulties
following an uneventful pregnancy and normal vaginal delivery at term. Her motor
development was delayed and she was unable to walk before 30 months of age. By age 12
she had difficulties rising from supine or squatting positions, managing stairs, was unable to
hop or jump, and suffered frequent falls. From the age of 17 years, she had several episodes
of spontaneous hip dislocations. Following birth of her first child at the age of 26 years, she
experienced increasing problems with reduced walking distance and difficulties with both
overhead and fine manual tasks. Exercise-induced myalgia and muscle stiffness prompted
by cold, sometimes with weakness affecting the hands, were frequent complaints. There was
no cognitive, bulbar or cardiorespiratory involvement.
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In addition, from the age of 18 she experienced repeated episodes of severe paralysis
initially affecting the legs and then rapidly spreading to the upper limbs lasting up to several
days. These episodes were typically preceded by a sensation of dizziness, facial and acral
paraesthesia, temporal pain and a visual aura comprising flashing lights, blurred vision and
diplopia. Respiratory, bulbar and sphincter functions were usually unimpaired. One episode
each was triggered by immersion in a cold swimming pool and another followed
administration of lignocaine for a minor surgical procedure, which also prompted marked
hyperpyrexia. Her episodes improved following commencement of a potassium-sparing,
high sodium diet.
She had four general anaesthetics for surgical procedures and did not experience any MH
reaction. Whilst only non-triggering anaesthetic agents were used for the last two
anaesthetics, no further details could be obtained regarding the first two anaesthetics
administered many years ago in different hospitals. She did not have any in vitro contracture
testing to formally assess for malignant hyperthermia susceptibility (MHS).
On a recent examination at 32 years of age, there was facial weakness with incomplete eye
closure and limitation of extraocular movements mainly on abduction and upgaze. She had
slight nasal escape on speaking and a high arched palate, with weak palatal movements but
no dysphonia. There was wasting of the deltoids and distal muscles in the upper limb. There
was marked axial weakness on trunk and neck flexion (MRC2), moderate limb girdle
weakness (MRC3/4) more pronounced in the shoulder than the hip girdle muscles with
additional distal weakness in the upper limbs pronounced in the first dorsal interosseoi
(MRC3). There was distal joint hyperlaxity, particularly affecting the hands. She had a
hyperlordotic stance but there was no kyphoscoliosis. No action or percussion myotonia was
evident. Forced vital capacity was 3.05 l. ECG was normal and an echocardiograph showed
no structural or functional abnormalities.
Muscle MRI of the lower limb performed as previously described [17] showed diffuse
involvement with relative sparing of the rectus femoris compared to the vasti, and the
anterior compartment compared to the gastrocnemius and the soleus within the lower leg, a
pattern suggestive of involvement of the RYR1 gene [4,17].
Concentric needle EMG showed myopathic changes in the left biceps and suggested chronic
neurogenic changes in the small hand muscles; there was no electrophysiological evidence
of myotonia. Cold immersion testing prompted profound weakness of the hands but
normally preserved CMAP responses in the right ADM both pre- and post-cooling,
suggesting cold-induced E–C uncoupling; EMG of the cooled small hand muscles showed
fibrillations and fasciculations with relatively large motor units. An exercise test for periodic
paralysis [18] performed at 21 years was within normal limits. The long exercise test
performed at the age of 30 years was negative but demonstrated an unexpected increase in
CMAP amplitude and area post-exercise. Oral potassium loading resulted in profound
paralysis more than 12 h after the loading but potassium levels were normal when measured
during the episode. A forearm ischaemic exercise test and routine laboratory investigations
including CK were normal.
2.2. Molecular genetic analysis
SCN4A and CLCN1 mutations were excluded by genomic DNA sequencing. The entire
coding regions (exon 1–106) of the RYR1 gene including splice sites were screened at both
genomic DNA and RNA levels. The entire coding sequence of the CACNA1S
(NM_000069.2) and CACNB1 (NM_000723.3) gene were also screened by using cDNA
synthesized from skeletal muscle as template.
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The patient had two muscle biopsies in early childhood and in her teens which suggested a
diagnosis of MmD. However, on review of her earlier biopsies appearances were less
suggestive of typical MmD associated with mutations in the selenoprotein N (SEPN1) gene
[19,20] and because of the diagnostic uncertainty repeat muscle biopsy samples were
obtained from the quadriceps (rectus femoris) at 30 years of age.
Cryostat sections were stained with haematoxylin and eosin (H&E), periodic acid Schiff
(PAS), nicotinamide dehydrogenase tetrazolium reductase (NADH-TR), succinate
dehydrogenase (SDH) and cytochrome oxidase (COX), according to standard procedures
[21]. Immunohistochemistry was done by double staining with primary antibodies: mouse
anti-RyR1 monoclonal antibody (1:500, Abcam) and goat anti-DHPR polyclonal antibody
(1:1000, Santa Cruz). Sections were incubated at room temperature for 1 h, and then washed
in phosphate buffered saline (PBS) and incubated 30 min at room temperature with anti-
mouse biotinylated secondary antibody (1:200, Amersham). After further washes in PBS,
sections were incubated at room temperature for 30 min with streptavidin-conjugated
Alexa-488 (1:1000, Molecular Probes) and donkey anti-goat Alexa-594 (1:1000, Molecular
Probes). Sections were viewed with a Leica fluorescent DMR microscope (Leica, Germany).
Images were captured digitally using Metamorph software (Universal Imaging Inc.) with
auto-exposure settings. To further investigate the distribution of the DHPR and RyR1
proteins, sections were also examined by high magnification confocal microscope (Zeiss
LSM 710, Germany).
Western blotting of RyR1 protein extracted from patient’s muscle, and routine
histopathological and immunohistochemical staining were performed as described
previously [21,22]. Band densities are relative to the respective desmin band, used as a
control of protein loading. The densitometric analyses were performed using Image J
software.
2.4. RyR1 functional studies
To determine the functional consequences of the p.Arg2939Lys mutation more directly,
RyR1-R2939K was constructed, expressed in HEK 293 cells, and crude membrane fractions
were prepared as previously described [23]. [3H]Ryanodine binding was used as a
measurement of RyR1 activity [24]. Specific [3H]ryanodine binding to membrane fractions
was determined for 20 h at 24 °C in 0.25 M KCl, 20 mM imidazole, pH 7 solution
containing 5 mM Mg2+, 5mM AMPPCP (a nonhydrozyableATP analog), 5 mM glutathione
(reduced) to mimick physiological conditions, 1.5–2.5 nM [3H]ryanodine and the indicated
concentrations of caffeine and free Ca2+ [23].
Voltage clamp studies were performed following expression of wild-type and mutant RyR1-
R2939K in RyR1-null myotubes from dyspedic mice as described previously [25]. The
whole-cell perforated voltage clamp technique was used to simultaneously measure L-type
Ca2+ currents (L-currents) and intracellular Ca2+ transients in expressing myotubes as
described previously [26].
3. Results
3.1. Molecular genetic analysis of the RYR1 gene
An apparently homozygous nucleotide variation of c.8816G>A was identified in exon 57 of
the RYR1 cDNA synthesized from patient’s skeletal muscle biopsy [22]. This maternally
inherited missense mutation affects the last nucleotide of exon 57 and caused a substitution
of p.Arg2939Lys. The p.Arg2939Lys mutation was not found neither in >200 normal
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control chromosomes from Caucasian populations nor among more than 50 previously
reported MHS/CCD individuals of both Caucasian and Asian origin in whom the entire
RYR1 coding sequence had been analyzed [27,28]. Furthermore, the c.8816G>A nucleotide
change, apparently homozygous in muscle, was heterozygous at the genomic DNA level
(Fig. 1), a discrepancy previously reported in MmD with ophthalmoplegia [4,6,8]. The
substituted arginine residue is strictly conserved in all three RyR isoforms and throughout
species (Fig. 2). Further sequencing of the RYR1 gene from lymphocyte-derived gDNA from
this patient eventually revealed an additional heterozygous c.6721 C>T substitution resulting
in a p.Arg2241X stop mutation, and an additional heterozygous c.2122G>A change
resulting in a p.Asp708Asn substitution on the same allele. mRNA produced from the allele
bearing these mutations was likely affected by nonsense-mediated decay, which would
account for the inability to amplify this allele from cDNA. In particular, the heterozygous c.
2122 G>A (p.Asp708Asn) substitution was undetectable at RNA level suggesting that both
this substitution and p.Arg2241X originate from the same allele that was not transcribed.
The p.Asp708Asn substitution changes a charged polar to an uncharged polar amino acid
and concerns a highly conserved residue. However, the fact that this substitution was not
transcribed at mRNA level makes a pathogenetic role unlikely. Maternal inheritance was
excluded for the c.6721 C>T (p.Arg2241X) and the c.2122G>A (p.Asp708Asn)
substitutions but no DNA was available from her father and siblings for further segregation
studies.
3.2. Light microscopy, immunohistochemistry and Western blot analysis of the muscle
biopsy
Muscle biopsy performed at 30 years showed increased variability in fibre size and increase
in internal nuclei in up to 25% of fibres. Internal nuclei were sometimes central and often
multiple (Fig. 3A, a and c). There was no excess endomysial connective tissue. There was
predominance of hypotrophic type 1 fibres (Fig. 3A, d). Core-like structures of varying size
were apparent with oxidative enzyme stains (Fig. 3A, b) and confirmed on electron
microscopy (Fig. 3A, e and f).
Double immunohistochemical labelling of control muscle with monoclonal antibodies to
RyR1 and DHPR proteins demonstrated nearly identical distribution pattern of the two
proteins as shown by the yellow staining in the merged image (Fig. 3B, f). However, in the
patient’s muscle reduced signal from the RyR1 protein (Fig. 3B, b and c) and abnormal
accumulation of DHPR protein in a subpopulation of fibres (Fig. 3B, a and c) were
observed. On further examination of biopsy sections by confocal microscope, unevenness of
stain with the RyR1 antibody was noted in regions corresponding to areas of distinct DHPR
aggregation (Fig. 4).
In order to quantify RyR1 protein in this patient we performed Western blot studies on
patient’s skeletal muscle. RyR1 protein expression levels assessed in Western blotting
analysis revealed a marked reduction of RyR1 protein content in the skeletal muscle biopsy
from the patient compared to that from a normal control individual (Fig. 3C). This is in
keeping with what we have reported recently in other patients with MmD and
ophthalmoplegia [22]. On densitometric analysis, there was only about 20% residual RyR1
protein expressed in skeletal muscle from the patient, less than expected due to nonsense-
mediated RNA decay of the allele harbouring the p.Arg2241X substitution alone.
3.3. RyR1 functional studies
[3H]Ryanodine binding is a sensitive method to evaluate regulation of RyR1 by its
endogenous and exogenous effectors [24]. As shown in Fig. 5A, membrane fractions
isolated from HEK 293 cells expressing wild type (WT) RyR1 and RyR1-R2939K showed a
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comparable bimodal Ca2+-dependence of [3H]ryanodine binding. We also probed the effects
of caffeine, an exogenous ligand known to augment RyR1 activation [24]. Fig. 5B shows
that caffeine increased to the same extent [3H]ryanodine binding to membranes containing
WT-RyR1 and RyR1-R2939K. The results suggest that the R2435K mutation did not affect
two characteristic functional properties of RyR1, as both Ca2+ dependence and activation by
caffeine were not altered.
Since the R2939K mRNA was the only RYR1 transcript detected in the skeletal muscle of
the patient, we compared EC coupling in dyspedic myotubes following homozygous
expression of either wild type RYR1 or R2939K. The whole-cell perforated patch clamp
technique was used to simultaneously assess the magnitude and voltage dependence of
depolarization-induced Ca2+ release (upper traces in Fig. 6A; “orthograde” coupling) and L-
type Ca2+ current density (lower traces in Fig. 6A; “retrograde” coupling). Peak L-current
density (Gmax) and the voltage dependence of channel activation (VG1/2) were not
significantly different between WT- and R2939K-expressing myotubes (Fig. 6B and Table
S1). Moreover, the magnitude (Fmax) and voltage dependence (VF1/2) depolarization-
induced Ca2+ release (Fig. 6C and Table S1) and DHPR–RyR1 co-localization
(Supplementary figure) were also not significantly different in WT- and R2939K-expressing
myotubes. Thus, the results presented in Figs. 4 and 5 indicate that the conservative R2939K
mutation identified in the patient does not directly alter RyR1 channel function.
4. Discussion
The distribution of wasting and weakness, histopathologic features and radiological findings
on muscle MRI in the patient reported in this paper are identical to those of other patients
with Multi-minicore disease (MmD) with external ophthalmoplegia attributed to
homozygosity [7], compound heterozygosity [4,8] or monoallelic expression of
heterozygous RYR1 missense mutations due to haploinsufficiency associated with either
epigenetic allele silencing [6] or nonsense-mediated RNA decay [8]. In addition, the patient
in this report exhibited clinical features suggestive of atypical periodic paralysis, not
previously reported to be associated with mutations in the RYR1 gene.
Despite suggestive symptoms, the precise nature of the periodic paralysis in our patient was
difficult to define and her presentation was clearly divergent from that seen in other forms of
genetically resolved periodic paralysis. Although clinical features, in particular exertional
myalgia, paralytic attacks precipitated by cold or K+-loading and improvement of symptoms
with a kaliuretic, were most suggestive of a form of hyperkalaemic periodic paralysis
(HYPP), there was no overt myotonia and the long and short exercise tests were negative.
Most importantly, measurement of serum K+-levels during a paralysis attack induced by K+-
administration were normal, suggesting normokalaemic periodic paralysis, a variant of
HYPP, by definition.
Regarding the mutations identified, several lines of evidence indicate their pathogenecity:
(1) the c.6721 C>T substitution leads to a premature stop codon, (2) no polymorphisms have
been previously reported at position 2939 and the amino acid residue is preserved across
different RyR isoforms and species, (3) compound heterozygosity for RYR1 nonsense and
missense mutations corresponds to findings in other patients with MmD and external
ophthalmoplegia [8], (4) the patient’s clinical presentation matches that associated with
monoallelic expression of paternally inherited missense mutations on a haploinsufficient
background due to epigenetic silencing of the maternal allele [6] and (5) other potential
causes of the periodic paralysis phenotype in this patient (e.g. mutations in CACNA1S and
SCN4A genes) were excluded.
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It seems unlikely that the co-occurrence of MmD and atypical periodic paralysis in the same
patient might be attributed to “double-trouble” due to an additional mutation in an as yet
unidentified gene, considering the combined clinical, neurophysiological and
immunohistochemical evidence for the RyR1-R2939K mutation altering proper RyR1 long-
term expression and stoichiometry of the EC coupling machinery in vivo. In particular, the
combination of profound weakness but preserved compound muscle action potentials
(CMAPs) in the hand muscles following cold immersion testing is unusual in the context of
other forms of periodic paralysis and suggests a temperature dependent, functionally
relevant disruption of EC coupling in the patient, in spite of normal calcium dependence of
ryanodine binding (Fig. 5) and voltage-gated calcium release following transient expression
in myotubes (Fig. 6). Altered DHPR–RYR1 stoichiometry in the patient’s muscle is
supported by reduced RyR1 expression (Fig. 3), as well as uneven and significant fiber-to-
fiber variability in RyR1/DHPR abnormal distribution (Figs. 3 and 4). Although episodes of
atypical periodic paralysis have not been previously described in other cases of RYR1-
related MmD with external ophthalmoplegia, this might be partly explained by a relatively
low penetrance of this particular trait. While our patient presented with features of a
congenital myopathy at birth, paralytic episodes did not develop until age 19 years and
responded favourably to commencement of a potassium sparing diet. Since many of the
patients with MmD with external ophthalmoplegia reported to date were infants or young
children [4], the periodic paralysis trait may not have developed at the time those cases were
reported. In addition, despite the lack of previously reported paralytic episodes in MmD with
external ophthalmoplegia, the marked sensitivity of muscle weakness to cold in these
individuals [4] points to a possible continuum between the congenital myopathy phenotype
and the manifestations of atypical periodic paralysis.
Our results indicate abnormal RyR1 protein expression and DHPR–RyR1 distribution in the
quadriceps of the patient in vivo, but, rather unexpectedly, normal RyR1 function and RyR1/
DHPR co-localization in vitro following transient homozygous expression of R2939K in
dyspedic myotubes. This apparent discrepancy could be explained by a slow time-dependent
quantitative, rather than qualitative, effect of the mutation, expressed homozygously on a
background of already reduced RyR1 protein due to nonsense-mediated RNA decay of the
second allele harbouring an allelic RYR1 nonsense mutation. Specifically, rather than
disrupting intrinsic RyR1 channel activity, the homozygous p.Arg2939Lys mutation may
alter the long-term stability of RyR1–DHPR interaction by affecting RyR1 junctional
localization and/or degradation, but unfortunately we were unable to obtain more stable
muscle cell lines to investigate this hypothesis further. Although the p.Arg2939Lys mutation
is a relatively conservative substitution, the presence of a lysine residue at this site could
potentially introduce a novel ubiquitination site that may alter the protein’s long-term
stability and/or localization [29]. An effect of the p.Arg2939Lys substitution on long-term
protein stability is also supported by the observation of in vivo RyR1 protein reduction to
only about 20% of the normal amount, much less than can be explained by nonsense-
mediated RNA decay of the allele harbouring the p.Arg2241X substitution alone. Impaired
stability of the DHPR/RyR1 complex has also been implicated in the zebrafish relatively
relaxed mutant, a model of MmD due to a nonsense mutation in the piscine fast muscle
ryanodine receptor isoform ryr1b [13]. Zebrafish relatively relaxed mutants harbouring this
mutation display similar findings of markedly reduced DHPR/RyR1 complexes associated
with an E–C uncoupling defect, further supporting a causative role of the RYR1 gene in the
corresponding human phenotype. As evidenced by the asymptomatic carrier mother of the
patient, heterozygosity for R2939K does not appear to be associated with a clinical
phenotype.
It remains uncertain whether the association of a congenital myopathy and an atypical form
of normokalaemic paralysis observed in our patient is unique or may also apply to other
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RYR1 mutations. Episodes of hyperkalaemic periodic paralysis have been described
previously in a genetically unresolved patient with an eye movement disorder, interpreted as
supranuclear gaze palsy, but possibly caused by external ophthalmoplegia in the context of
an MmD phenotype [30]. More recently, a causative association between periodic paralysis
and a RYR1 substitution, c.7025A>G, was initially postulated in a patient with both MHS
and periodic paralysis but later rejected because of identification of the same change in other
unrelated patients with MHS but without periodic paralysis [16]. However, as RYR1
screening in these patients was performed at the genomic and not muscle-derived cDNA
level, potential monoallelic vs. biallelic RYR1 expression in muscle potentially explaining
the discrepancy between phenotypes could not therefore be excluded. “Unmasking” of
mutations due to monoallelic RYR1 allele expression has emerged as an important
mechanism in the pathogenesis of MmD and ophthalmoplegia [6,8]. Some RYR1 mutations
may therefore behave as dominant with regard to MHS, but recessives with regard to
congenital myopathy (e.g. MmD) and possible other phenotypes (e.g. atypical periodic
paralysis), an hypothesis further supported by the lack of myopathic and paralytic symptoms
in the asymptomatic carrier parent of our patient.
Whilst mutations in the SCN4A and the CACNA1S gene have been firmly established as the
most common cause of hyper- and hypokalaemic forms of periodic paralyses, a substantial
proportion of patients presenting with classic clinical features of these conditions remain
genetically unresolved. In a large cohort of 226 patients from 56 families with periodic
paralysis [31], almost 40% had no confirmed SCN4A or CACNA1S mutation. Interestingly,
mild fixed weakness between episodes without defined myopathic changes other than the
vacuolar pathology commonly observed with CACNA1S mutations and less frequently with
SCN4A mutations is suggestive of an associated myopathy in this subgroup of genetically
unresolved cases.
Our findings indicate a new, RYR1-related form of periodic paralysis and suggest the RYR1
gene is a candidate for genetically unresolved cases of periodic paralysis, particularly those
with symptoms divergent from genetically resolved forms of periodic paralysis and
additional features of a congenital myopathy. The characteristic muscle MRI found in RYR1
related diseases could be helpful in raising the possibility of involvement of the RYR1 gene.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Chromatograms showing expression of the c.8816G>A substitution in genomic DNA and
skeletal muscle-derived cDNA. In the patient the substitution is heterozygous (A/G) at the
genomic DNA level but homozygous at the transcriptional level (A), suggesting that the
wild type allele (carrying nucleotide G) is not transcribed in the patient’s skeletal muscle.
The c.8816G>A mutation was maternally inherited. Since the change in this patient affected
the last nucleotide residue in exon 57, the sequences following this residue differed between
DNA and cDNA.
Zhou et al. Page 11














Amino acid sequence alignment of the residues flanking the mutated arginine residue at
position 2939 in RyR1. Residues conserved across different RyR isoforms and species are
shaded. The substituted arginine residue is strictly conserved in all three RyR isoforms and
across all species.
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Analysis of muscle biopsies. (A) Histochemical and electron microscopic analysis of
transverse sections obtained from a biopsy of the patient’s quadriceps muscle. H&E (a) and
Gomori trichrome (c) stains show marked variability in fibre size with increased internal
nucleation in the absence of excess connective or fatty tissue. ATPase stain pre-incubated at
pH 9.4 (d) and cytochrome oxidase (COX) stain (b) are consistent with marked type 1 fiber
predominance. Uneven COX staining reveals core-like structures in some fibres. Electron
microscopy (e & f) demonstrates variable degrees of sarcomeric disorganization, ranging
from Z-band streaming to more advanced disarray of myofibrils. (B) Immunohistochemical
distribution of DHPR and RyR1 protein in transverse sections obtained in the patient (a-c)
and a normal control (d-f). In most fibres, reduced RyR1 immunofluorescence as well as the
aggregation of DHPR in some fibres are observed in the patient compared to normal control
(c & f). (C) Western blot analysis of skeletal muscle tissue. Protein extracted from patient’s
muscle biopsy shows a significant reduction of RyR1 expression (565kDa) compared to the
control sample. Desmin immunoreactivity was used as a muscle-specific internal control.
Semi-quantification by using densitometric analyses showed that in the patient there was
only about 20% residual RyR1 protein expressed (result expressed as percentage of control).
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Double staining sections were examined by confocal microscope at high magnification (40×
objective). Compared to control biopsy, patient’s muscle fibre showed abnormal
accumulation of DHPR protein and slight reduction of RyR1 antibody staining in the
corresponding area (arrows).
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Calcium (A) and caffeine (B) dependence of [3H]ryanodine binding to recombinant WT
RyR1 and the R2939K RyR1 mutant. Specific [3H]ryanodine binding to crude membrane
fractions containing WT or R2939K mutant RyR1 was determined as described in Methods.
Data represent the mean of 3 independent experiments. There is no difference in Ca2+ or
caffeine dependence of [3H] ryanodine binding to WT RyR1 (closed circles) and R2939K
mutant RyR1 (closed triangles).
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Comparison of DHPR-RyR1 coupling in dyspedic myotubes expressing either wild-type
(WT) RyR1 or R2939K (RK). A: Representative voltage-gated Ca2+ transients (upper
traces) and L-type Ca2+ currents (lower traces) recorded in response to 200ms depolarizing
pulses to the indicated membrane potentials from WT-(left) and R2939Kexpressing (right)
dyspedic myotubes. B: Average (±SEM) I-V curves for dyspedic myotubes expressing WT
RYR1 (closed circles; n=21) and RyR1-R2939K (open circles; n = 21). The average values
for the parameters obtained by separately fitting each myotube within a group are given in
Supplementary Table S1. C: Average voltage dependence of SR Ca2+ release for dyspedic
myotubes expressing WT-(closed circles; n=21) and R2939K-expressing (open circles;
n=21) dyspedic myotubes. The average values (±SEM) for the parameters obtained by
separately fitting each myotube within a group are given in Supplementary Table S1.
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